Łukasz Krzemiński

Doctor of Biological Sciences with over 15 years of experience in the field of molecular biophysics, bioelectrochemistry and biosensors, innovative research tools, drug discovery assays, and mechanistic biology studies. A graduate of Biotechnology and Chemistry at the Nicolaus Copernicus University in Torun (PL). In 2012, he obtained his PhD at the University of Leeds (UK) by constructing biosensors and studying the catalytic mechanisms of redox enzymes using innovative protein film voltammetry PFV, impedance spectroscopy EIS, and fluorescence microscopy methods. During his PhD, he completed research internships at Leiden University (NL) and Copenhagen University (DN) concerning metalloproteins and biological electron transport studies. Through 2012-2015 he continued his research as a Postdoctoral Associate at Cornell University (USA), where he studied molecular functions of individual proteins in living cells using single-molecule super resolution fluorescence microscopy PALM and the original modification of the PALM-BiFC method. In 2015-2020, he was associated with the biotechnology company OncoArendi Therapeutics SA (PL), where he led research identifying small molecule inhibitors binding non-enzymatic protein in the YKL-40 program (patent author) and implemented a new drug discovery program based on deubiquitinases (DUBs). Leader of an Exploratory Group aimed at launching drug discovery programs based on new therapeutic targets. Author of numerous scientific publications (14 publications, 459 citations, h-index = 10). Since 2020, the initiator and co-founder of Biosens Labs Ltd.